Debio-1347 (CAS 1265229-25-1)
Alternate Names:
Debio1347 Debio 1347 CH5183284 CH 5183284 CH-5183284 zoligratinib
CAS Number:
1265229-25-1
Molecular Weight:
356.40
Molecular Formula:
C20H16N6O
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Debio-1347 (CAS 1265229-25-1) References
- Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3-BAIAP2L1. | Nakanishi, Y., et al. 2015. Mol Cancer Ther. 14: 704-12. PMID: 25589496
- FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review). | Katoh, M. 2016. Int J Mol Med. 38: 3-15. PMID: 27245147
- A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations. | Voss, MH., et al. 2019. Clin Cancer Res. 25: 2699-2707. PMID: 30745300
- TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma. | Goyal, L., et al. 2019. Cancer Discov. 9: 1064-1079. PMID: 31109923
- The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder. | Roskoski, R. 2020. Pharmacol Res. 151: 104567. PMID: 31770593
- FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma. | Cleary, JM., et al. 2021. Cancer Discov. 11: 2488-2505. PMID: 33926920
- Debio1347, an Oral FGFR Inhibitor: Results From a Single-Center Study in Pediatric Patients With Recurrent or Refractory FGFR-Altered Gliomas. | Farouk Sait, S., et al. 2021. JCO Precis Oncol. 5: PMID: 34250399
- Dose-Dependent and Reversible Serous Retinal Detachments in Fibroblast Growth Factor Receptor Inhibitor-Associated Retinopathy. | Parikh, D., et al. 2023. Ophthalmic Surg Lasers Imaging Retina. 54: 368-370. PMID: 37233117
- Targeting the fibroblast growth factor pathway in molecular subtypes of castration-resistant prostate cancer. | Labrecque, MP., et al. 2024. Prostate. 84: 100-110. PMID: 37796107
- Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial. | Grivas, P., et al. 2024. Clin Cancer Res.. PMID: 38771739
Inhibitor of:
Bek, bFGF, FGF-2, FGFR-3, FGFR-4, FGFR1OP2, FIBP, FIGNL1, Flg, FRRS1, FRS3, and Haspin.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Debio-1347, 10 mg | sc-507386 | 10 mg | $324.00 |